AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8592957 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Intensity (LI; n = 7)
Number of subjects: 26
Study 8592957 — intervention group
Group type: COMPARATOR
Intervention: Control (CON; n = 11)
Number of subjects: 26
Study 2650517 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous diltiazem (0.25 mg/kg/2 minutes followed by 0.35 mg/kg/2 minutes if needed)
Number of subjects: 113
Study 2650517 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 113
Study 2650517 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous diltiazem after placebo
Number of subjects: 113
Study 2650517 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous diltiazem
Number of subjects: 113
Study 410740 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolmetin and glibenclamide
Number of subjects: 40
Study 410740 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 31539075 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 4289
Study 31539075 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiangiogenic agents
Number of subjects: 4289
Study 31539075 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-epidermal growth factor receptor agents
Number of subjects: 4289
Study 30591684 — intervention group
Group type: COMPARATOR
Intervention: Normal eating rate (6 min for 600 kcal meal)
Number of subjects: 21
Study 30591684 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow eating rate (24 min for 600 kcal meal)
Number of subjects: 21
Study 26481267 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) simulation training
Number of subjects: 40
Study 26481267 — intervention group
Group type: COMPARATOR
Intervention: Traditional cadaveric dissection training
Number of subjects: 40
Study 24489841 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-level intervention designed to increase testing and lower HIV incidence
Number of subjects: 657
Study 22987084 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Number of subjects: 1830
Study 22987084 — intervention group
Group type: COMPARATOR
Intervention: Control (no trastuzumab)
Number of subjects: 1830
Study 19804445 — intervention group
Group type: EXPERIMENTAL
Intervention: Temperature modulation on histamine stimulus (32 degrees C to 25 degrees C) in lesional skin (LS)
Number of subjects: 22
Study 19804445 — intervention group
Group type: EXPERIMENTAL
Intervention: Temperature modulation on histamine stimulus (32 degrees C to 25 degrees C) in nonlesional skin (NLS)
Number of subjects: 22
Study 19804445 — intervention group
Group type: COMPARATOR
Intervention: Healthy skin (HS) of age-matched volunteers
Number of subjects: 22
Study 19804445 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional MRI analysis during itch provocation in NLS
Number of subjects: 22
Study 19804445 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional MRI analysis during itch provocation in LS
Number of subjects: 22
Study 17656284 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermaxillary fixation (IMF) screw
Number of subjects: 40
Study 17656284 — intervention group
Group type: COMPARATOR
Intervention: No intermaxillary fixation (IMF) screw
Number of subjects: 40
Study 16084050 — intervention group
Group type: EXPERIMENTAL
Intervention: Rolimeter knee tester
Number of subjects: 30
Study 12230317 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet habitually high in fresh fruits and vegetables, modest in calories and alcohol, and low in red meat and animal fat
Number of subjects: 0
Study 12230317 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium, folate, and selenium
Number of subjects: 0
Study 12230317 — intervention group
Group type: EXPERIMENTAL
Intervention: Phytochemicals (plant-based compounds)
Number of subjects: 0
Study 12230317 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensible amount of calories and maintaining a desirable weight
Number of subjects: 0
Study 10436712 — intervention group
Group type: EXPERIMENTAL
Intervention: Policosanol 10 mg/day
Number of subjects: 106
Study 10436712 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin 20 mg/day
Number of subjects: 106
Study 10436712 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 10 mg/day
Number of subjects: 106
Study 8522641 — intervention group
Group type: EXPERIMENTAL
Intervention: Single 50 mg, 100 mg, and 200 mg oral doses of nefazodone hydrochloride
Number of subjects: 18
Study 8522641 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice daily doses of 50 mg, 100 mg, and 200 mg of nefazodone hydrochloride for 7.5 days
Number of subjects: 18
Study 8522641 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefazodone hydrochloride
Number of subjects: 18
Study 2224266 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive suggestions tape
Number of subjects: 63
Study 2224266 — intervention group
Group type: COMPARATOR
Intervention: Blank tape
Number of subjects: 63
Study 231594 — intervention group
Group type: EXPERIMENTAL
Intervention: BCNU, radiation, and hydroxyurea (HU) on alternate days during radiation (BHR)
Number of subjects: 0
Study 231594 — intervention group
Group type: COMPARATOR
Intervention: BCNU and radiation (BR)
Number of subjects: 0
Study 30085251 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma potassium (K+) levels
Number of subjects: 831760
Study 28452101 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined low-dose spironolactone plus vitamin E
Number of subjects: 0
Study 28452101 — intervention group
Group type: COMPARATOR
Intervention: Vitamin E monotherapy
Number of subjects: 0
Study 25824210 — intervention group
Group type: EXPERIMENTAL
Intervention: Posaconazole 300 mg in tablet form with a high-fat meal
Number of subjects: 18
Study 25824210 — intervention group
Group type: COMPARATOR
Intervention: Posaconazole 300 mg in tablet form in fasted state
Number of subjects: 18
Study 25824210 — intervention group
Group type: COMPARATOR
Intervention: Posaconazole oral suspension with a high-fat meal
Number of subjects: 18
Study 23720786 — intervention group
Group type: EXPERIMENTAL
Intervention: GH treatment (0.05 mg/kg recombinant human GH daily)
Number of subjects: 73
Study 22143218 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Counseling Integration Program
Number of subjects: 37
Study 22143218 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 37
Study 19017878 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic Pneumatic Compression Devices (PCDs)
Number of subjects: 35
Study 19017878 — intervention group
Group type: COMPARATOR
Intervention: Sham Devices
Number of subjects: 35
Study 18072840 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive smoking cessation intervention (three 1-hr counseling sessions plus 8 weeks of nicotine patch therapy)
Number of subjects: 118
Study 18072840 — intervention group
Group type: COMPARATOR
Intervention: Brief smoking cessation intervention (15-min counseling session with 5 min of follow-up)
Number of subjects: 118
Study 18072840 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive smoking cessation intervention
Number of subjects: 118
Study 18072840 — intervention group
Group type: COMPARATOR
Intervention: Brief smoking cessation intervention
Number of subjects: 118
Study 16294460 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg 17beta‐E2/0.25 mg TMG
Number of subjects: 1218
Study 16294460 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg 17beta‐E2/0.125 mg TMG
Number of subjects: 1218
Study 16294460 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg E2V/1 mg NET
Number of subjects: 1218
Study 12478329 — intervention group
Group type: EXPERIMENTAL
Intervention: Telithromycin 800 mg once daily
Number of subjects: 404
Study 12478329 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin 1,000 mg three times a day
Number of subjects: 404
Study 12478329 — intervention group
Group type: EXPERIMENTAL
Intervention: Telithromycin (subset analysis)
Number of subjects: 404
Study 12478329 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin (subset analysis)
Number of subjects: 404
Study 12478329 — intervention group
Group type: EXPERIMENTAL
Intervention: Telithromycin
Number of subjects: 404
Study 12478329 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin
Number of subjects: 404
Study 9890248 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Number of subjects: 157
Study 9890248 — intervention group
Group type: COMPARATOR
Intervention: Nonteratogenic antibiotics (Control)
Number of subjects: 157
Study 7654891 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 150 mg daily
Number of subjects: 489
Study 7654891 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg daily
Number of subjects: 489
Study 2478340 — intervention group
Group type: EXPERIMENTAL
Intervention: 53.3 g albumin as part of blood replacement therapy, followed by 20 g albumin daily for the first three postoperative days
Number of subjects: 18
Study 2478340 — intervention group
Group type: COMPARATOR
Intervention: No albumin
Number of subjects: 18
Study 786001 — intervention group
Group type: EXPERIMENTAL
Intervention: Human chorionic gonadotropin (HCG)
Number of subjects: 51
Study 786001 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 31881232 — intervention group
Group type: EXPERIMENTAL
Intervention: Egg oral immunotherapy (OIT)
Number of subjects: 0
Study 31370717 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein (ProLYOtin; arm A)
Number of subjects: 47
Study 31370717 — intervention group
Group type: COMPARATOR
Intervention: Placebo (arm B)
Number of subjects: 47
Study 29135370 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted dose of Ribavirin (ADJ)
Number of subjects: 181
Study 29135370 — intervention group
Group type: COMPARATOR
Intervention: Standard dose of Ribavirin (STD)
Number of subjects: 181
Study 25938474 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate
Number of subjects: 450
Study 25938474 — intervention group
Group type: COMPARATOR
Intervention: Daily oral antipsychotics
Number of subjects: 450
Study 24156203 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium nitrate dentifrice
Number of subjects: 212
Study 24156203 — intervention group
Group type: EXPERIMENTAL
Intervention: 8.0% arginine with calcium carbonate dentifrice
Number of subjects: 212
Study 24156203 — intervention group
Group type: COMPARATOR
Intervention: Fluoride dentifrice
Number of subjects: 212
Study 21613498 — intervention group
Group type: EXPERIMENTAL
Intervention: Tactile-auditory sensory substitution training over 5 days
Number of subjects: 9
Study 21613498 — intervention group
Group type: EXPERIMENTAL
Intervention: Tactile-auditory sensory substitution training
Number of subjects: 9
Study 20115934 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive glycemic control
Number of subjects: 0
Study 20115934 — intervention group
Group type: COMPARATOR
Intervention: Standard antidiabetic treatment
Number of subjects: 0
Study 16925888 — intervention group
Group type: EXPERIMENTAL
Intervention: PA$$ (promotional activities and financial support)
Number of subjects: 150
Study 16925888 — intervention group
Group type: EXPERIMENTAL
Intervention: PA (promotional activities)
Number of subjects: 150
Study 16925888 — intervention group
Group type: COMPARATOR
Intervention: Comparison between PA$$ and PA
Number of subjects: 150
Study 14760265 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin prick test (SPT) with wheal size <5 mm
Number of subjects: 162
Study 14760265 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin prick test (SPT) with wheal size >=5 mm
Number of subjects: 162
Study 14760265 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk-specific IgE <2 kU/L
Number of subjects: 162
Study 14760265 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk-specific IgE >=2 kU/L
Number of subjects: 162
Study 14760265 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed reactions to cow's milk
Number of subjects: 162
Study 14760265 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate reactions to cow's milk
Number of subjects: 162
Study 11728609 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathological Gambling Disorder (PGD)
Number of subjects: 114
Study 9224847 — intervention group
Group type: EXPERIMENTAL
Intervention: Static Closed Loop (SCL)
Number of subjects: 0
Study 9224847 — intervention group
Group type: COMPARATOR
Intervention: Full Open Loop (FOL)
Number of subjects: 0
Study 7970937 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticotropin-releasing hormone (CRH) administration (1 microgram/kg i.v. bolus)
Number of subjects: 16
Study 7970937 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticotropin-releasing hormone (CRH) administration
Number of subjects: 16
Study 7970937 — intervention group
Group type: COMPARATOR
Intervention: Metyrapone administration (450 mg/m2/dose every 4 h x seven doses)
Number of subjects: 16
Study 7970937 — intervention group
Group type: COMPARATOR
Intervention: Metyrapone administration
Number of subjects: 16
Study 3301758 — intervention group
Group type: EXPERIMENTAL
Intervention: Misonidazole (2.0 gm/m2/wk X 6 doses) with altered fractionation (2.5 Gy in a.m., 2.1 Gy in p.m.)
Number of subjects: 306
Study 3301758 — intervention group
Group type: EXPERIMENTAL
Intervention: Misonidazole (2.0 gm/m2/wk X 6 doses)
Number of subjects: 306
Study 3301758 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone (control)
Number of subjects: 306
Study 31985558 — intervention group
Group type: EXPERIMENTAL
Intervention: Art therapy
Number of subjects: 54
Study 31985558 — intervention group
Group type: EXPERIMENTAL
Intervention: Reminiscence therapy
Number of subjects: 54
Study 31985558 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (regular activities)
Number of subjects: 54
Study 30313053 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol (0.5 mg/kg bolus followed by infusion of 5 to 15 μg/kg/min)
Number of subjects: 70
Study 30313053 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 70
Study 30313053 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol
Number of subjects: 70
Study 30313053 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 70
Study 28599212 — intervention group
Group type: COMPARATOR
Intervention: 7.5mg THC
Number of subjects: 42
Study 28599212 — intervention group
Group type: COMPARATOR
Intervention: 12.5mg THC
Number of subjects: 42
Study 28599212 — intervention group
Group type: COMPARATOR
Intervention: 0mg THC (Placebo)
Number of subjects: 42
Study 25620378 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (30 mg/day)
Number of subjects: 48
Study 25620378 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 24155052 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual placement and support
Number of subjects: 0
Study 24155052 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 20923446 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical Aloe vera (AV) 0.4 ml (70% concentration) three times a day
Number of subjects: 64
Study 20923446 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 20923446 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical Aloe vera (AV)
Number of subjects: 64
Study 18421055 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported social functioning (measured using EORTC QLQ-C30)
Number of subjects: 564
Study 18421055 — intervention group
Group type: EXPERIMENTAL
Intervention: WBC count
Number of subjects: 564
Study 18421055 — intervention group
Group type: EXPERIMENTAL
Intervention: Alkaline phosphatase (AP)
Number of subjects: 564
Study 18421055 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of metastatic sites
Number of subjects: 564
Study 17260222 — intervention group
Group type: EXPERIMENTAL
Intervention: Regime A: 400 microg of intravaginal misoprostol every 3 h
Number of subjects: 138
Study 17260222 — intervention group
Group type: EXPERIMENTAL
Intervention: Regime B: loading dose of 600 microg, followed by 200 microg every 3 h
Number of subjects: 138
Study 14659328 — intervention group
Group type: EXPERIMENTAL
Intervention: epirubicin/vinorelbine and sequential paclitaxel (EV/T)
Number of subjects: 54
Study 14659328 — intervention group
Group type: COMPARATOR
Intervention: epirubicin/cyclophosphamide plus sequential paclitaxel (EC/T)
Number of subjects: 54
Study 14659328 — intervention group
Group type: COMPARATOR
Intervention: epirubicin/vinorelbine (EV)
Number of subjects: 54
Study 14659328 — intervention group
Group type: COMPARATOR
Intervention: epirubicin/cyclophosphamide (EC)
Number of subjects: 54
Study 11265381 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial laryngectomy with reconstruction of defects using a vascular pedicle flap of the submandibular gland
Number of subjects: 81
Study 11265381 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention mentioned)
Number of subjects: 81
Study 8829944 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia with diamorphine (2 mg initial dose, 0.2 mg h-1 background infusion, 0.2 mg on-demand doses with a 15 min lockout)
Number of subjects: 22
Study 8829944 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia with diamorphine
Number of subjects: 22
Study 1449278 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin
Number of subjects: 148
Study 1449278 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 148
Study 3906431 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenobarbitone
Number of subjects: 12
Study 3906431 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 29497279 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg eletriptan HBr
Number of subjects: 16
Study 29497279 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg eletriptan HBr
Number of subjects: 16
Study 29497279 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg eletriptan HBr
Number of subjects: 16
Study 29497279 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg eletriptan HBr (repeated oral dose 2 h apart)
Number of subjects: 16
Study 26856226 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban 60/30 mg
Number of subjects: 0
Study 26856226 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 0
Study 24281285 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual therapy protocol (5 sessions)
Number of subjects: 89
Study 24281285 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 89
Study 24281285 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual therapy protocol
Number of subjects: 89
Study 22571284 — intervention group
Group type: EXPERIMENTAL
Intervention: Total knee arthroplasty (TKA) in addition to optimised non-surgical treatment
Number of subjects: 100
Study 22571284 — intervention group
Group type: COMPARATOR
Intervention: Optimised non-surgical treatment alone
Number of subjects: 100
Study 20472597 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 508
Study 20472597 — intervention group
Group type: COMPARATOR
Intervention: Sequential monotherapy
Number of subjects: 508
Study 20472597 — intervention group
Group type: COMPARATOR
Intervention: Step-up combination therapy
Number of subjects: 508
Study 20472597 — intervention group
Group type: COMPARATOR
Intervention: Initial combination with prednisone
Number of subjects: 508
Study 20472597 — intervention group
Group type: COMPARATOR
Intervention: Initial combination with infliximab
Number of subjects: 508
Study 18357884 — intervention group
Group type: EXPERIMENTAL
Intervention: 25% AlCl3
Number of subjects: 40
Study 18357884 — intervention group
Group type: EXPERIMENTAL
Intervention: 15.5% Fe2(SO4)3
Number of subjects: 40
Study 18357884 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% HCl‐epinephrine
Number of subjects: 40
Study 18357884 — intervention group
Group type: COMPARATOR
Intervention: Sodium chloride
Number of subjects: 40
Study 15796287 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm air drying while rubbing for 15 seconds
Number of subjects: 30
Study 15796287 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm air drying without ultraviolet light while holding hands stationary
Number of subjects: 30
Study 15796287 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm air drying with ultraviolet light
Number of subjects: 30
Study 15796287 — intervention group
Group type: EXPERIMENTAL
Intervention: Three sheets of paper towel drying
Number of subjects: 30
Study 15796287 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm air drying while holding hands stationary, paper towels, and warm air drying while rubbing hands
Number of subjects: 30
Study 15796287 — intervention group
Group type: EXPERIMENTAL
Intervention: Paper towels
Number of subjects: 30
Study 12836812 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimatoprost 0.03%
Number of subjects: 31
Study 12836812 — intervention group
Group type: COMPARATOR
Intervention: Travoprost 0.004%
Number of subjects: 31
Study 10374215 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone 2.5 mg/day
Number of subjects: 97
Study 10374215 — intervention group
Group type: COMPARATOR
Intervention: Conjugated equine estrogens 0.625 mg/day with norgestrel 0.15 mg/day
Number of subjects: 97
Study 8911002 — intervention group
Group type: EXPERIMENTAL
Intervention: 720 EL. U of hepatitis A antigen
Number of subjects: 0
Study 8911002 — intervention group
Group type: EXPERIMENTAL
Intervention: 1440 EL. U of hepatitis A antigen
Number of subjects: 0
Study 8911002 — intervention group
Group type: EXPERIMENTAL
Intervention: 720 EL. U and 1440 EL. U of hepatitis A antigen
Number of subjects: 0
Study 1989570 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling plus six individual sessions of stress prevention training
Number of subjects: 1307
Study 1989570 — intervention group
Group type: COMPARATOR
Intervention: Standard counseling
Number of subjects: 1307
Study 1989570 — intervention group
Group type: COMPARATOR
Intervention: Counseling plus a three-session interactive video program
Number of subjects: 1307
Study 7065478 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral terbutaline (2.5-5.0 mg)
Number of subjects: 14
Study 7065478 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 31706187 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention arm
Number of subjects: 6738
Study 31706187 — intervention group
Group type: COMPARATOR
Intervention: Placebo arm
Number of subjects: 6738
Study 30816637 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib 400 mg by mouth daily
Number of subjects: 28
Study 30816637 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28